» Articles » PMID: 11378002

More 'malignant' Than Cancer? Five-year Survival Following a First Admission for Heart Failure

Overview
Publisher Wiley
Date 2001 May 30
PMID 11378002
Citations 255
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The prognostic impact of heart failure relative to that of 'high-profile' disease states such as cancer, within the whole population, is unknown.

Methods: All patients with a first admission to any Scottish hospital in 1991 for heart failure, myocardial infarction or the four most common types of cancer specific to men and women were identified. Five-year survival rates and associated loss of expected life-years were then compared.

Results: In 1991, 16224 men had an initial hospitalisation for heart failure (n=3241), myocardial infarction (n=6932) or cancer of the lung, large bowel, prostate or bladder (n=6051). Similarly, 14842 women were admitted for heart failure (n=3606), myocardial infarction (n=4916), or cancer of the breast, lung, large bowel or ovary (n=6320). With the exception of lung cancer, heart failure was associated with the poorest 5-year survival rate (approximately 25% for both sexes). On an adjusted basis, heart failure was associated with worse long-term survival than bowel cancer in men (adjusted odds ratio, 0.89; 95% CI, 0.82-0.97; P<0.01) and breast cancer in women (odds ratio, 0.59; 95% CI, 0.55-0.64; P<0.001). The overall population rate of expected life-years lost due to heart failure in men was 6.7 years/1000 and for women 5.1 years/1000.

Conclusion: With the notable exception of lung cancer, heart failure is as 'malignant' as many common types of cancer and is associated with a comparable number of expected life-years lost.

Citing Articles

Versatile whey acidic protein four-disulfide core domain proteins: biology and role in diseases.

Wen Y, Jiang N, Wang Z, Xiao Y Front Cell Dev Biol. 2024; 12:1459129.

PMID: 39296934 PMC: 11408880. DOI: 10.3389/fcell.2024.1459129.


The genetic association between hyperthyroidism and heart failure: a Mendelian randomization study.

Liu J, Wu G, Li S, Cheng L, Ye X Front Endocrinol (Lausanne). 2024; 15:1344282.

PMID: 38681769 PMC: 11045892. DOI: 10.3389/fendo.2024.1344282.


Stem Cell Therapy against Ischemic Heart Disease.

Tsai I, Sun C Int J Mol Sci. 2024; 25(7).

PMID: 38612587 PMC: 11011361. DOI: 10.3390/ijms25073778.


Prevalence and impact of sarcopenia in individuals with heart failure with reduced ejection fraction (the SARC-HF study): A prospective observational study protocol.

Correa Nascimento P, Rodrigues Junior L, Mediano M, Goncalves da Silva V, Tura B, Nogueira F PLoS One. 2024; 19(3):e0300918.

PMID: 38512827 PMC: 10956824. DOI: 10.1371/journal.pone.0300918.


At the Heart of Resilience: Empowering Women's Agency in Navigating Cardiovascular Disease.

Code J CJC Open. 2024; 6(2Part B):473-484.

PMID: 38487058 PMC: 10935683. DOI: 10.1016/j.cjco.2023.12.013.